D-erythro-Sphingosine-1-phosphate CAS: 26993-30-6
MF: C18H38NO5P
MW: 379.48
A ligand for EDG-1 and EDG-3 and activator of GPR3, GPR6, and GPR12.

D-erythro-Sphingosine-1-phosphate (CAS 26993-30-6)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 124ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
D-erythro-Sphingosine-1-phosphate is rated 5.0 out of 5 by 1.
5
1
4
0
3
0
2
0
1
0
Nomi alternativi: (2S,3R,4E)-2-Amino-4-octadecene-1,3-diol 1-(Dihydrogen phosphate); Sphingosine-1-phosphate
Applicazione: A ligand for EDG-1 and EDG-3 and activator of GPR3, GPR6, and GPR12
Numero CAS: 26993-30-6
Purezza: ≥95%
Peso molecolare: 379.48
Formula molecolare: C18H38NO5P
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
* Vedere Certificato di Analisi per informazioni sul lotto specifico (incluso il contenuto d'acqua).

D-erythro-Sphingosine-1-phosphate(S1P) is a polar sphingolipid metabolite which regulates diverse cellular responses including cell growth, survival and migration. S1P was reported to stimulate DNA synthesis and cell division in quiescent cultures of Swiss 3T3 fibroblasts and to trigger the dual signal transduction pathways of calcium mobilization and PC-PLD (phospholipase D) activation. S1P serves as a second messenger for intracellular calcium mobilization in U-937 cells (sc-2239) and decreases cellular cAMP. Recent studies show that S1P is a G-protein-coupled receptor (GPCR) ligand for the EDG-1 family, including EDG-1, -3, -5, -6 and -8. This bioactive lipid mediator has been shown to stimulate the ERK pathway and to also counteract the ceramide-induced activation of stress-activated protein kinase (SAPK/JNK). Researchers have also found that S1P is a strong inhibitor of cell motility and phagokinesis in B16 melanoma cells. Additionally, it induces rapid and transient tyrosine phosphorylation of epidermal growth factor receptor (EGFR) and c-Met in gastric cancer cells. S1P has also been known as a tumor-promoting lipid. Suggested to be an activator of GPR3, GPR6, and GPR12. D-erythro-Sphingosine-1-phosphate is an activator of EDG-1, EDG-3, EDG-2, EDG-4 and EDG-5.


Referenze

1. Van Veldhoven, P.P., et al. 1989. J. Lipid Res. 30: 611-616. PMID: 2754341
2. Desai, N.N., et al. 1992. J. Biol. Chem. 267: 23122-23128. PMID: 1429659
3. Sadahira, Y., et al. 1992. Proc. Natl. Acad. Sci. U.S.A. 89: 9686-9690. PMID: 1409683
4. Olivera, A. and Spiegel, S. 1993. Nature. 365: 557-560. PMID: 8413613
5. Mattie, M., et al. 1994. J. Biol. Chem. 269: 3181-3188. PMID: 8106352
6. Wu, J., et al. 1995. J. Biol. Chem. 270: 11484-11488. PMID: 7744787
7. Choi, O.H., et al. 1996. Nature. 380: 634-636. PMID: 8602265
8. Cuvillier, O., et al. 1996. Nature. 381: 800-803. PMID: 8657285
9. Spiegel, S., et al. 2000. Biochim. Biophys. Acta. 1484: 107-116. PMID: 10760461
10. Spiegel, S. and Milstien, S. 2000. FEBS Lett. 476: 55-57. PMID: 10878250
11. Shida, D., et al. 2004. FEBS Lett. 577: 333-338. PMID: 15556605
12. Watterson, K.R., et al. 2005. Cell. Signal. 17: 289-298. PMID: 15567060

Aspetto :
Powder
Stato fisico :
Solid
Solubilità :
Soluble in 0.3M NaOH (~4 mg/ml). Insoluble in water.
CONSERVAZIONE :
Store at -20° C
Punto di scioglimento :
179-189° C
Indice di rifrazione :
n20D 1.50
IC50 :
Sphingosine 1-phosphate receptor Edg-1 : IC50 = 0.78 nM (human); Sphingosine 1-phosphate receptor Edg-8: IC50 = 2 nM (human); Sphingosine 1-phosphate receptor Edg-6: IC50 = 1.04 nM (human); Sphingosine 1-phosphate receptor Edg-3 : IC50 = 0.92 nM (human)
Valori pK :
pKa: 1.76, pKb: 9.8
Solo per uso in Ricerca. Non previsto per Uso Diagnostico o Terapeutico.
WGK Germania :
3
RTECS :
RG2260500
PubChem CID :
Numero MDL :
MFCD00270077
SMILES :
CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O

Download SDS (MSDS)

CERTIFICATO DI ANALISI

Adobe Acrobat Reader necessario per una visualizzazione affidabile,
stampa e commenta sui documenti PDF

D-erythro-Sphingosine-1-phosphate (CAS 26993-30-6)  Citazioni prodotti

Vedi quanti altri hanno usato D-erythro-Sphingosine-1-phosphate (CAS 26993-30-6). Clicca sulla voce per laccesso a PubMed .

Ciatazioni 1 a5 di 5 totali

PMID: # 31455837  2019. Cancer Gene Ther.

PMID: # 17255471  Novgorodov, AS. et al. 2007. FASEB J. 21: 1503-1514.

PMID: # 16926156  El-Shewy, HM. et al. 2006. J. Biol. Chem. 281: 31399-31407.

PMID: # 15377653  Argraves, KM. et al. 2004. J. Biol. Chem. 279: 50580-50590.

PMID: # 12855693  Pettus, BJ. et al. 2003. J. Biol. Chem. 278: 38206-38213.

Ciatazioni 1 a5 di 5 totali
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 113ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 11ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

La Santa Cruz Biotechnology, Inc. è un leader mondiale nello sviluppo di prodotti per il mercato della ricerca biomedica. Chiamaci al numero gratuito 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. Tutti i diritti riservati. "Santa Cruz Biotechnology", ed il logo Santa Cruz Biotechnology, Inc."Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", il logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", ed "EZ Touch" sono marchi registrati dalla Santa Cruz Biotechnology, Inc.
Tutti i marchi sono proprietà dei rispettivi proprietari.